Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers

被引:13
|
作者
Purrington, Kristen S. [1 ,3 ]
Gorski, David [1 ,2 ,4 ]
Simon, Michael S. [1 ,3 ]
Hastert, Theresa A. [1 ,3 ]
Kim, Seongho [1 ,3 ]
Rosati, Rayna [1 ,4 ]
Schwartz, Ann G. [1 ,3 ]
Ratnam, Manohar [1 ,4 ]
机构
[1] Wayne State Univ, Sch Med, Dept Oncol, 4100 John R, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Michael & Marian Ilitch Dept Surg, Detroit, MI USA
[3] Barbara Ann Karmanos Canc Inst, Populat Studies & Dispar Res Program, Detroit, MI 48201 USA
[4] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI USA
关键词
Gene expression; Pathology; Clinical outcomes; Racial disparities; ENDOCRINE THERAPY; GENE-EXPRESSION; RECURRENCE; WOMEN; ASSAY; VALIDATION; TAMOXIFEN; BENEFIT; RISK; RACE;
D O I
10.1007/s10549-020-05607-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background African American women (AAW) die more frequently from estrogen receptor (ER) positive breast cancer than European American women (EAW). We investigated the relationship between race, percent ER staining, treatment, and clinical outcomes. Methods Percent ER staining (weakly ER+: 1-10%, moderately ER+: 11-50%, strongly ER+: > 50%) was abstracted from pathology reports for 1573 women with ER+/HER2- invasive breast cancer treated at a single cancer center in Detroit, MI from 2010 to 2017. Clinical outcomes and tumor characteristics were obtained from the Metropolitan Detroit Cancer Surveillance System. Associations of ER levels with demographic and clinical characteristics were evaluated using logistic regression. Overall and breast cancer-specific (BCS) survival were evaluated using Cox proportional hazards models. Results AAW were more likely to have tumors with lower ER staining levels than EAW (weakly ER+: Odds ratio (OR) 2.19, p = 0.019; moderately ER+: OR 2.80, p = 0.005). Women with weakly compared to strongly ER+ tumors were less likely to receive endocrine therapy (ET) regardless of race (OR 0.79, p < 0.001). Mortality was predicted by both AA race (Overall hazard ratio (HR) = 1.72, p < 0.001; BCS HR 1.45, p = 0.08) and low (1-50%) ER (Overall HR 1.57, p = 0.083; BCS HR 2.11, p = 0.017) adjusting for clinic-pathologic characteristics. ET was associated with improved BCS survival in all women (1-50%: HR 0.11, p < 0.001; > 50%: HR 0.24, p < 0.001). Conclusion The biology of ER+/HER2- tumors varies by race, although this does not appear to account for racial differences in survival. Although ET substantially reduces mortality among women with weakly ER+ tumors, these women are less likely to be treated with ET and have poorer outcomes.
引用
收藏
页码:145 / 154
页数:10
相关论文
共 50 条
  • [21] Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers
    Yagi, Tomoko
    Inoue, Natsuko
    Yanai, Ayako
    Murase, Keiko
    Imamura, Michiko
    Miyagawa, Yoshimasa
    Enomoto, Yukie
    Nishimukai, Arisa
    Takatsuka, Yuichi
    Hirota, Seiichi
    Akazawa, Kouhei
    Miyoshi, Yasuo
    BREAST CANCER, 2016, 23 (02) : 224 - 230
  • [22] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 74 - 76
  • [23] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 74 - 76
  • [24] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Hao, Shuang
    Shao, Zhi-Ming
    BMC MEDICINE, 2015, 13
  • [25] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Ke-Da Yu
    Yi-Zhou Jiang
    Shuang Hao
    Zhi-Ming Shao
    BMC Medicine, 13
  • [26] Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
    Hai-long Chen
    Feng-bo Huang
    Qiang Chen
    Yong-chuan Deng
    BMC Cancer, 23
  • [27] WHY ARE ESTROGEN-RECEPTOR-NEGATIVE BREAST CANCERS MORE AGGRESSIVE THAN THE ESTROGEN-RECEPTOR-POSITIVE BREAST CANCERS
    SHEIKH, MS
    GARCIA, M
    PUJOL, P
    FONTANA, JA
    ROCHEFORT, H
    INVASION & METASTASIS, 1994, 14 (1-6): : 329 - 336
  • [28] Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
    Chen, Hai-long
    Huang, Feng-bo
    Chen, Qiang
    Deng, Yong-chuan
    BMC CANCER, 2023, 23 (01)
  • [29] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [30] Optimal duration of neoadjuvant exemestane treatment in elderly women with estrogen receptor-positive/HER2-negative breast cancer
    Takei, H.
    Saito, T.
    Ishikawa, Y.
    Hayashi, Y.
    Kurosumi, M.
    Kai, T.
    Tabei, T.
    BREAST, 2011, 20 : S75 - S75